Update
$Replimune (REPL.US)$ Replimune: Positive Topline Primary Analysis Data by Independent Central Review From Ignyte Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma! Intends to submit BLA in 2H 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
